RxDoctor Payments Data

Sonia Velez, MD

Family Medicine · Yonkers, NYNPI 1215902010

Payments from drug & device makers

$547in general payments, 2019–2025

Across 12 payments — averaging $45.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$263
  • Esperion Therapeutics, Inc.$125
  • Amgen$42
  • GSK$36
  • Abbott$26
  • Sunovion Pharmaceuticals Inc.$21
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$547 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$2,428
Medicare patients
17
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$28,102
OzempicSemaglutide27$26,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,110
JanuviaSitagliptin Phosphate23$15,003
Bydureon BciseExenatide Microspheres12$9,292
FarxigaDapagliflozin Propanediol14$8,931
VascepaIcosapent Ethyl23$7,043
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,864
Albuterol Sulfate HfaAlbuterol Sulfate78$2,858
Atorvastatin Calcium245$1,729
Ventolin HfaAlbuterol Sulfate17$964
Diclofenac Sodium17$913
Lubiprostone14$804
Metformin Hcl140$572
Rosuvastatin Calcium55$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$36$16,11025 claims
MerckJanuvia$16$15,00323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Yonkers

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →